

# Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy



## Supplementary data

Tochukwu C Okwuosa<sup>1</sup>, Beatriz Pereira<sup>1</sup>, Basel Arafat<sup>1</sup>, Milena Cieszyńska<sup>1</sup>, Abdullah Isreb<sup>1</sup>, Mohamed A Alhnan<sup>1\*</sup>


<sup>1</sup> School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK

---


\*Corresponding author: [MAIbedAlhnan@uclan.ac.uk](mailto:MAIbedAlhnan@uclan.ac.uk)




**Figure S1** Impact of lubricants on (A) TGA thermal degradation profiles of PVP filament and (B) the *in vitro* release pattern of theophylline from core.



**Figure S2** DSC thermographs of Eudragit L100-55, TEC and talc (raw materials), filament and 3D printed shell.



**Figure S3** TGA thermal degradation profiles of the raw materials of; theophylline, PVP, TBP, TEC as well as the physical mixture, the filament and the 3D printed tablets.



**Figure S4** Reversing DSC thermographs of PVP, PVP: TEC (12.5%) filament, as well as diclofenac-loaded filaments (first heat-scan).